Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New Stent-Grafts aim to fix dangerous aortic bulges without major surgery

NCT ID NCT02266719

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how well new, custom-made and off-the-shelf stent-grafts work for repairing complex aortic aneurysms (bulges in the main artery). About 750 people with aneurysms in the abdomen, chest, or arch will be treated using a less invasive procedure through blood vessels. The goal is to see if these devices are safe and effective at preventing rupture while reducing radiation exposure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 750 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2014

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

General Inclusion Criteria A patient is deemed suitable for inclusion in the study if the patient has at least one of the following: 1. Juxtarenal or suprarenal AAA, type I-IV thoracoabdominal aortic aneurysms or aortic arch aneurysms or dissections with a diameter ≥5.0 cm in diameter or 2 times the normal aortic diameter 2. Aneurysm with a history of growth ≥0.5 cm/year 3. Saccular aneurysm with an aortic diameter greater than 1.5 times the normal aortic diameter that is deemed to be at risk for rupture based upon physician interpretation. 4. Patients who are not eligible for treatment with commercially available endografts. 5. Presence of concomitant thoracoabdominal and aortic arch aneurysm meeting one of the above-mentioned criteria. General Exclusion Criteria A patient must be excluded from the clinical investigation if any of the following are true: 1. Age \<18 years 2. Life expectancy \<2 years 3. Pregnant, breastfeeding, or planning on becoming pregnant within 60 months; 4. Inability or refusal to give informed consent by the patient or a legally authorized representative; 5. Unwilling or unable to comply with the follow-up schedule 6. Prior surgical or interventional procedure within 30 days of the anticipated date of the fenestrated procedure, except for planned staged procedures to provide access for repair (e.g. staged iliac conduit, thoracic endovascular aortic aneurysm repair for proximal aneurysms, elephant trunk repair), to facilitate the procedure by allowing open reparation of a target artery not amenable to revascularization with the investigational device, such us an internal iliac artery, subclavian artery or visceral artery with early bifurcation, tortuosity or occlusive disease preventing successful placement and alignment side stents, or to treat proximal aortic aneurysms. 7. Participation in another clinical or device trial, except observational studies, participation in another investigational endovascular endograft protocol, percutaneous aortic valve protocol, or concomitant clinical trials designed to evaluate medical therapy strategies to reduce perioperative risk during fenestrated-branched endovascular repair, including risks of renal dysfunction, contrast-induced nephropathy, neurologic, spinal cord or cardiac complications, and/or use of advanced imaging to reduce radiation exposure during implantation of these devices. Participation in investigational device trials not encompassed by the IDE protocol should be performed remotely from the fenestrated/branched repair (\>30 days). Participation in a medical therapy trial or advanced imaging trial designed to improve peri-operative outcomes or to reduce radiation exposure of fenestrated/branched endografts may be concurrent with the IDE study. Examples include therapy directed to reduce rates of spinal cord injury, stroke, and contrast-induced nephropathy associated with implantation of fenestrated-branched stent-grafts or advanced imaging trials designed to reduce radiation exposure during repair. 8. Patients with ruptured aortic aneurysm requiring urgent or emergent repair, except patients with contained, stable ruptures with anatomy suitable for an off-the-shelf design. 9. Patients who meet anatomical criteria for commercially available aortic stent-grafts according to the proposed instructions for use of these devices. Medical Exclusion Criteria Patients must be excluded from the study if any of the following conditions are true: 1. Known sensitivities or allergies to stainless steel, nitinol, polyester, solder (tin, silver), polypropylene, urethane, or gold 2. History of anaphylactic reaction to contrast material that cannot be adequately pre-medicated 3. Leaking or ruptured aneurysm associated with hypotension 4. Uncorrectable coagulopathy 5. Mycotic aneurysm or patients with evidence of active systemic infection. 6. History of connective tissue disorder (e.g. vascular Ehlers Danlos, Marfan syndrome), except those patients who had prior open surgical aortic replacement or endovascular repair, where a surgical graft or an endograft would serve as landing zone for the investigational endograft, those who are deemed prohibitive risk for open repair or connective tissue disorders with no vascular effects (e.g. non-vascular types of Ehlers Danlos). 7. Body habitus that would inhibit x-ray visualization of the aorta and its branches. Anatomical Exclusion Criteria Patient must be excluded from the study if any of the following are true: 1. Inadequate femoral or iliac access compatible with the requirements of the required delivery system. 2. Inability to perform a temporary or permanent open surgical or endovascular iliac conduit for patients with inadequate femoral/iliac access. 3. Absence of a landing aortic segment in the distal thoracic aorta above the diaphragmatic hiatus with: 1. A diameter measured from the outer wall greater than 42 mm or less than 19 mm 2. Parallel aortic wall with \>20% diameter change and with significant calcification and/or thrombus in the selected area of the seal zone. 4. Visceral anatomy not compatible with the investigational device due to excessive occlusive disease or small size not amenable to stent graft placement. 5. Unsuitable distal iliac arterial fixation site and anatomy: 1. Common iliac artery fixation site diameter measured outer wall to outer wall on a section image (CT)\< 8.0 mm, with inability to perform surgical conduit. 2. Iliac artery diameter measured outer wall to outer wall on a sectional image (CT) \> 21 mm at the distal fixation site, with inability to perform open internal iliac artery revascularization or iliac branch stent graft or custom iliac extension with fenestration. 3. Iliac artery distal fixation site \<10 mm in length. 4. Inability to preserve at least one hypogastric artery. For patients in the type I-III TAAA cohort, the intended use criteria are the same for both the fenestrated/branched CMD vs the off-the-shelf device. The CMD will preferably be used, unless an urgent repair is indicated or the waiting period for design or manufacturing of the CMD is considered unacceptable. Additional anatomical inclusion criteria for aortic arch devices 1. Proximal aortic fixation zone: 1. Native aorta or surgical graft 2. Diameter: 20-42mm 3. Proximal neck length ≥ 20mm 4. Ascending aortic length ≥50mm 5. Must occur distal to coronary arteries and any coronary artery bypass grafts that are considered patent and necessary for proper cardiac perfusion 2. Distal aortic fixation zone: 1. Native aorta or surgical graft 2. Diameter: 20-42mm 3. Distal neck length ≥20mm 4. Distal fixation will be obtained with stent-grafts in a staged repair 3. Supra-aortic trunk (brachiocephalic) vessels 1. The arch branch device will typically have two or three branches with additional modifications to the design that allow for a single branch or a combination of branch and scallop if a customized version is required. An extra-anatomic bypass graft may be done in conjunction (or in a staged fashion) with the procedure, as required. For the two-branch design, the vessels most commonly incorporated will be the innominate artery and the left common carotid artery. However, the innominate artery may be coupled with the left subclavian artery in the setting of a bovine arch, whereby the flow to the left carotid would come from a left subclavian to carotid bypass. Similarly, the left carotid and subclavian artery may be branched, or simply one vessel branched, should specific anatomic limitations exist. In such a situation, multiple extra-anatomic bypasses may be necessary. A design with a single subclavian retrograde branch and scallop to the left carotid artery may be used to extend the landing zone to Zone 1. Finally, a design with two antegrade inner branches for the innominate and left common carotid, and one retrograde inner branch for the left subclavian artery may be used in select cases. Thus, the inclusion criteria are defined for each artery, yet any combination of arteries may be used for a repair. i. Innominate artery 1\. Native vessel or surgical graft 2\. Diameter: 8-22mm 3\. Length of sealing zone ≥10mm 4\. Acceptable tortuosity ii. Left (or right) common carotid artery 1. Native vessel or surgical graft 2. Diameter 6-16mm 3. Length of sealing zone ≥10mm 4. Acceptable tortuosity iii. Left (or right) subclavian artery 1. Native vessel or surgical graft 2. Diameter: 5-20mm 3. Length of sealing zone ≥10mm 4. Acceptable tortuosity 4\. In the setting of an aortic dissection, the following criteria must exist: 1. Access into the true lumen from the groin and at least one supra-aortic trunk vessel 2. A sealing zone in the target aorta (or surgical graft) that is proximal to the primary dissection, such that a stent-graft would be anticipated to seal off the dissection lumen 3. A sealing zone in the target supra-aortic trunk vessels that is distal to the dissection, anticipated to seal off the dissection lumen, or surgically created 4. A true lumen size large enough to deploy the device and still gain access into the target branches 5\. In the setting of more distal disease, the repair may be coupled with a thoracoabdominal branched device, infrarenal device, and/or internal iliac branch device. 6\. Iliac anatomy must allow for the delivery of the arch branch device, which is loaded within a 20F-24F sheath. Conduits to the iliac vessels or aorta may be used if deemed necessary.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aortic aneurysm, abdominal are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Emory Clinic

    Atlanta, Georgia, 30322, United States

  • Emory Hospital

    Atlanta, Georgia, 30322, United States

  • Emory University

    Atlanta, Georgia, 30322, United States

  • University of Texas Southwestern Medical Center

    Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.